Connect Sign In
Nearly 85% of respondents to an ARUP survey believe the FDA’s proposed rule to regulate lab-developed tests will negatively impact their labs. Only 3% believe they have the financial resources to comply.
ARUP and the University of Utah Department of Pathology have announced that ARUP’s executive vice president, Julio Delgado, MD, MS, will be the inaugural holder of a new presidential endowed chair.
ARUP and Medicover have partnered to provide a new companion diagnostic test to European Union patients. The test helps identify individuals eligible for a new gene therapy for severe hemophilia A.
Utah Business magazine honored ARUP Laboratories with its Best Companies to Work For award for the sixth consecutive year based on anonymous employee survey results.
ARUP believes the FDA’s plan to regulate lab-developed tests will limit access to testing, increase costs, and face a court challenge, and is calling for collaboration to better address LDT oversight.
ARUP has gained a Conformité Européenne (CE) mark for AAV5 DetectCDx™ single-site use. The test will aid in determining the eligibility of non-U.S. patients for a new hemophilia A gene therapy.
A platform clients use to reduce testing waste, lower cost per test, and improve patient safety has won the prestigious Choosing Wisely Champion Award from the American Society for Clinical Pathology.
New ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine™ will improve patient lives by advancing groundbreaking diagnostic and prognostic technologies.
The FDA now recommends the same assessment questions for all donors, regardless of gender or sexual orientation. ARUP Blood Services is one of the first donor centers to update processes in response.
ARUP Laboratories has received FDA approval for its companion diagnostic immunoassay, AAV5 DetectCDx™, which helps determine patient eligibility for a new gene therapy for severe hemophilia A.
